article thumbnail

TechCrunch+ roundup: New VC rules, AI biotech investor survey, Instagram ad case study

TechCrunch

6 investors discuss why AI is more than just a buzzword in biotech. In her latest investor survey, Anna Heim spoke to six biotech investors about where AI creates value, short-term market shifts, and how they’d like to be approached by founders: Robert Mittendorff, M.D, general partner and head of healthcare, B Capital.

Biotech 215
article thumbnail

As AI pervades biotech, what are investors looking for in 2023?

TechCrunch

JP Morgan’s announcement comes at a time when, in the words of B Capital general partner and head of healthcare Robert Mittendorff M.D, “public market biotechs are dramatically down as interest rates rise and the focus on near-term development outweighs the promise of longer-term results and approvals.”

Biotech 246
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

6 investors discuss why AI is more than just a buzzword in biotech

TechCrunch

That’s why we weren’t very surprised when a slew of investors told us they rarely see a biotech startup that doesn’t incorporate AI in some form or other these days. But despite becoming quite the buzzword, AI’s apparent ubiquity in biotech isn’t actually driving deal flow or higher valuations.

Biotech 242
article thumbnail

TechCrunch+ roundup: Using predictive LTV, Boston VC survey, active learning for ML teams

TechCrunch

” Going private: A guide to PE tech acquisitions Biotech proved a surprisingly bright spot in 2022’s startup correction Image Credits: Getty Images The hard science and regulations that govern biotech companies sets them far apart from other startups. biotech deals also set new records in 2022 for both median deal size, $33.5

Biotech 212
article thumbnail

These 5 investors are betting on helping you live longer and better

TechCrunch

Health span versus life span, longevity for pets versus humans, biotech versus wellness, seniors versus young people, dependency versus autonomy, prevention versus treatment, analytics, education, infrastructure.” He added, “There are multiple angles to solve problems for very heterogeneous groups with different requirements.

Biotech 313
article thumbnail

5 investors explain why longevity tech is a long-term play

TechCrunch

We’re widening our lens, looking for more — and more diverse — investors to include in TechCrunch surveys where we poll top professionals about challenges in their industry. If you’re an investor who’d like to participate in future surveys, fill out this form.

Biotech 227
article thumbnail

11 investors predict a colorful, if difficult, future for psychedelic startups

TechCrunch

A recent survey by TechCrunch+ indicates that investors and founders are, instead of simply looking for attractive opportunities, increasingly putting their minds to building the foundations for an industry that can employ the power of psychedelics to change lives. Will they take the lead?”

Biotech 248